# First-Line Chemotherapy and Panitumumab in Advanced Non-Small Cell Lung Cancer

> **NCT01038037** · PHASE2 · TERMINATED · sponsor: **Vejle Hospital** · enrollment: 23 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Vinorelbine
- **DRUG:** panitumumab

## Key facts

- **NCT ID:** NCT01038037
- **Lead sponsor:** Vejle Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-01
- **Primary completion:** 2013-06
- **Final completion:** 2013-12
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** 1. Very low enrollment rate.
2. Recent studies question the effect of adding panitumumab in this category of patients.
3. Too high toxicity rate
- **Last updated:** 2014-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01038037

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01038037, "First-Line Chemotherapy and Panitumumab in Advanced Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01038037. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*